Upstream Bio, Inc.
UPB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002022626
In the last 90 days, Upstream Bio, Inc. insiders filed 0 open-market purchases and 5 sales; 148 institutions reported holding it in 13F filings for Q2 2026, worth $350.1M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Upstream Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 5 insiders, $27.6K in total
- Insiders trading
- 5
- Net value
- −$27.6K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Upstream Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Gray Michael | CFO and COO | 27,942 | Sep 17, 2026 | 4 |
| Ambrose Allison | General Counsel | 15,563 | Sep 17, 2026 | 4 |
| Deykin Aaron | Chief Medical Officer | 32,302 | Sep 17, 2026 | 4 |
| Sutherland Everett Rand | Chief Executive Officer | 68,717 | Sep 17, 2026 | 4 |
| Houghton Adam | Chief Business Officer | 22,901 | Sep 17, 2026 | 4 |
| Renaud Ronald C JR | Director | – | Jun 11, 2026 | 1 |
| Beckman Daniella | Director | – | Jun 11, 2026 | 1 |
| Ratcliffe Liam | Director | – | Jun 11, 2026 | 1 |
| Chimovits Erez | Director | 4,554,873Indirect | Jun 11, 2026 | 1 |
| Fleming Harold Edward | Director | – | Jun 11, 2026 | 1 |
| Ruddy Marcella K. | Director | – | Jun 11, 2026 | 1 |
| OrbiMed Advisors LLC | Director, 10% Owner | 4,554,873Indirect | Oct 17, 2024 | 0 |
| OrbiMed Israel GP II, L.P. | Director, 10% Owner | 4,554,873Indirect | Oct 17, 2024 | 0 |
| OrbiMed Advisors Israel II Ltd | Director, 10% Owner | 4,554,873Indirect | Oct 17, 2024 | 0 |
| OrbiMed Capital GP VIII LLC | Director, 10% Owner | 4,554,873Indirect | Oct 17, 2024 | 0 |
| Blavatnik Len | 10% Owner | 5,494,410 | Oct 17, 2024 | 0 |
| Access Industries Holdings LLC | 10% Owner | 5,494,410 | Oct 17, 2024 | 0 |
| Access Industries Management, LLC | 10% Owner | 5,494,410 | Oct 17, 2024 | 0 |
| AI Biotechnology LLC | 10% Owner | 5,494,410 | Oct 17, 2024 | 0 |
| AI Upstream LLC | 10% Owner | 5,494,410 | Oct 17, 2024 | 0 |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10% Owner | 894,733 | Oct 15, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)4:05 PM ET | Sep 16 | 1 day | Gray MichaelCFO and COO | SSale | −853 | $5.49 | −$4.68K | −3.0%27.9K after | |
| Sep 17, 2026 (view filing)4:05 PM ET | Sep 16 | 1 day | Ambrose AllisonGeneral Counsel | SSale | −485 | $5.49 | −$2.66K | −3.0%15.6K after | |
| Sep 17, 2026 (view filing)4:05 PM ET | Sep 16 | 1 day | Deykin AaronChief Medical Officer | SSale | −895 | $5.49 | −$4.91K | −2.7%32.3K after | |
| Sep 17, 2026 (view filing)4:05 PM ET | Sep 16 | 1 day | Sutherland Everett RandChief Executive Officer | SSale | −2.10K | $5.49 | −$11.5K | −3.0%68.7K after | |
| Sep 17, 2026 (view filing)4:05 PM ET | Sep 16 | 1 day | Houghton AdamChief Business Officer | SSale | −700 | $5.49 | −$3.84K | −3.0%22.9K after | |
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | Gray MichaelCFO and COO | SSale | −853 | $6.10 | −$5.20K | −2.9%28.8K after | |
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | Sutherland Everett RandChief Executive Officer | SSale | −2.10K | $6.10 | −$12.8K | −2.9%70.8K after | |
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | Houghton AdamChief Business Officer | SSale | −700 | $6.10 | −$4.27K | −2.9%23.6K after | |
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | Deykin AaronChief Medical Officer | SSale | −895 | $6.10 | −$5.46K | −2.6%33.2K after | |
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | Ambrose AllisonGeneral Counsel | SSale | −477 | $6.10 | −$2.91K | −2.9%16.0K after | |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Gray MichaelCFO and COO | SSale | −852 | $9.29 | −$7.92K | −2.8%29.6K after | |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Deykin AaronChief Medical Officer | SSale | −894 | $9.29 | −$8.31K | −2.7%32.7K after | |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Sutherland Everett RandChief Executive Officer | SSale | −2.09K | $9.29 | −$19.4K | −2.8%72.9K after | |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Ambrose AllisonGeneral Counsel | SSale | −475 | $9.29 | −$4.41K | −2.8%16.5K after | |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Houghton AdamChief Business Officer | SSale | −699 | $9.29 | −$6.49K | −2.8%24.3K after | |
| Oct 17, 2024 (view filing)4:17 PM ET | Oct 15 | 2 days | OrbiMed Advisors LLC and 3 othersDirector, 10% Owner | PPurchase | +825.0K | $17.00 | +$14.0M | +22.1%4.55M after | 2 lotsDuplicate filing |
| Oct 17, 2024 (view filing)4:05 PM ET | Oct 15 | 2 days | Blavatnik Len and 4 others10% Owner | PPurchase | +1.18M | $17.00 | +$20.0M | New position1.18M after | 10b5-1 |
| Oct 17, 2024 (view filing) | Oct 15 | 2 days | Chimovits ErezDirector, 10% Owner | PPurchase | +825.0K | $17.00 | +$14.0M | +22.1%4.55M after | 2 lots |